AIMS: To establish the prevalence of c-erbB-2 protein expression in a surgical series of Barrett's adenocarcinomas; and to correlate this expression with clinicopathological data and prognosis. METHODS: Sixty six surgical specimens of Barrett's adenocarcinomas were included in this retrospective study. Blocks of the tumour and of non-dysplastic Barrett's mucosa were stained with a polyclonal antibody specific for the intracytoplasmic domain of the c-erbB-2 protein. RESULTS: Seven of 66 tumours showed membrane staining for the c-erbB-2 protein. The non-dysplastic Barrett's mucosa was negative in all cases. There was no difference between c-erbB-2 positive and negative tumours with regard to mean age, sex ratio, percentage of alcohol misusers, percentage of smokers, tumour differentiation, depth of invasion, lymph node response, and proliferative activity, assessed by the percentage of tumour cells positive with the MIB-1 antibody directed against the Ki-67 antigen. All c-erb B2 positive tumours were of Lauren's intestinal type compared with negative c-erbB-2 tumours. Patients with c-erbB-2 positive tumours had a significantly poorer prognosis than patients with negative tumours. CONCLUSIONS: The prevalence of Barrett's adenocarcinomas expressing c-erbB-2 found in this study (11%) was similar to that observed in published series of gastric adenocarcinomas. c-erbB-2 protein expression could be an important prognostic indicator in Barrett's adenocarcinoma.
AIMS: To establish the prevalence of c-erbB-2 protein expression in a surgical series of Barrett's adenocarcinomas; and to correlate this expression with clinicopathological data and prognosis. METHODS: Sixty six surgical specimens of Barrett's adenocarcinomas were included in this retrospective study. Blocks of the tumour and of non-dysplastic Barrett's mucosa were stained with a polyclonal antibody specific for the intracytoplasmic domain of the c-erbB-2 protein. RESULTS: Seven of 66 tumours showed membrane staining for the c-erbB-2 protein. The non-dysplastic Barrett's mucosa was negative in all cases. There was no difference between c-erbB-2 positive and negative tumours with regard to mean age, sex ratio, percentage of alcohol misusers, percentage of smokers, tumour differentiation, depth of invasion, lymph node response, and proliferative activity, assessed by the percentage of tumour cells positive with the MIB-1 antibody directed against the Ki-67 antigen. All c-erb B2 positive tumours were of Lauren's intestinal type compared with negative c-erbB-2tumours. Patients with c-erbB-2 positive tumours had a significantly poorer prognosis than patients with negative tumours. CONCLUSIONS: The prevalence of Barrett's adenocarcinomas expressing c-erbB-2 found in this study (11%) was similar to that observed in published series of gastric adenocarcinomas. c-erbB-2 protein expression could be an important prognostic indicator in Barrett's adenocarcinoma.
Authors: T Yamamoto; S Ikawa; T Akiyama; K Semba; N Nomura; N Miyajima; T Saito; K Toyoshima Journal: Nature Date: 1986 Jan 16-22 Impact factor: 49.962
Authors: Y Yonemura; I Ninomiya; S Ohoyama; S Fushida; H Kimura; K Tsugawa; T Kamata; A Yamaguchi; I Miyazaki; Y Endou Journal: Oncology Date: 1992 Impact factor: 2.935
Authors: I Ninomiya; Y Endo; Y Yonemura; M Noguchi; S Fushida; M Nakai; H Takamura; F Harada; T Suzuki; I Miyazaki Journal: Br J Cancer Date: 1992-07 Impact factor: 7.640
Authors: Daniel Vallböhmer; Paul Marjoram; Hidekazu Kuramochi; Daisuke Shimizu; Hsuan Jung; Steve R DeMeester; Daniel Oh; Parakrama T Chandrasoma; Kathleen D Danenberg; Tom R DeMeester; Peter V Danenberg; Jeffrey H Peters Journal: J Gastrointest Surg Date: 2007-09 Impact factor: 3.452
Authors: R Langer; B H A Von Rahden; J Nahrig; C Von Weyhern; R Reiter; M Feith; H J Stein; J R Siewert; H Höfler; M Sarbia Journal: J Clin Pathol Date: 2006-06 Impact factor: 3.411
Authors: Oana M Radu; Tyler Foxwell; Kathleen Cieply; Sarah Navina; Sanja Dacic; Katie S Nason; Jon M Davison Journal: Am J Clin Pathol Date: 2012-04 Impact factor: 2.493
Authors: Agnieszka M Rygiel; Francesca Milano; Fiebo J Ten Kate; Jacques J G H M Bergman; Kausillia K Krishnadath Journal: J Oncol Date: 2010-06-09 Impact factor: 4.375
Authors: Ellie Chan; Lizette Vila Duckworth; Ahmad Alkhasawneh; Tania Zuluaga Toro; Xiaomin Lu; Kfir Ben-David; Steven J Hughes; Georgios Rossidis; Robert Zlotecki; Judith Lightsey; Karen C Daily; Long Dang; Carmen J Allegra; Brent King; Thomas J George Journal: J Gastrointest Oncol Date: 2016-04